INTRODUCTION
Costello syndrome (OMIM #218040) is characterized by severe feeding problems in infancy, short stature, coarse facial features with full lips and a large mouth, curly or sparse, fine hair, cardiac abnormalities, including tachyarrhythmia and hypertrophic cardiomyopathy, a predisposition to papillomata and malignant tumors, as well as neurologic abnormalities, including intellectual disability, nystagmus and hypotonia (1) . Heterozygous germline mutations in the protooncogene HRAS underlie Costello syndrome (2) .
HRAS serves as signal transducer by alternating between an active guanosine triphosphate (GTP)-bound and inactive guanosine diphosphate (GDP)-bound state. The kinetics of GDP dissociation and GTP hydrolysis are modulated by two classes of proteins: Guanine nucleotide exchange factors (GEFs) activate HRAS by mediating the exchange of GDP for GTP, whereas GTPase-activating proteins (GAPs) stimulate the low intrinsic GTPase activity, thereby negatively controlling RAS function (3, 4) . In the active state, HRAS binds to a number of effector proteins, such as serine/threonine RAF kinases, the catalytic subunits of phosphoinositide 3-kinase (PI3K), phospholipase C1 (PLCE1) and RAL guanine nucleotide dissociation stimulator (RALGDS) (5) . As a result, signal flow via these HRAS target proteins is increased.
More than 80% of patients with Costello syndrome share the same HRAS mutation, c.34G.A (p.G12S), that is associated with the typical and relatively homogeneous phenotype (6, 7) . The functional consequences of mutations of HRAS amino acid 12 were extensively studied due to their prominent role in oncogenic transformation. Such alterations affect intrinsic and GAP-stimulated hydrolytic activity of HRAS and thus maintain the active form and decouple HRAS from incoming signals (8 -11) . Therefore, 'gain-of-function' and 'hyperactivation' concerning HRAS downstream signaling pathways are widely accepted as the molecular basis of Costello syndrome. Functional characterization of rarer HRAS germline mutations, however, revealed additional molecular consequences/pathomechanisms, including altered GDP/GTP nucleotide affinities (p.K117R) (12) and inefficient effector binding (p.E37dup) (13) . Such rare HRAS germline mutations have been reported in individuals with attenuated phenotypes (p.T58I, p.K117R, pA146T, p.A146V and p.E37dup) (12) (13) (14) (15) (16) or congenital myopathy and variable features resembling Costello syndrome (p.Q22K and p.E63K) (17) . Furthermore, individuals with Costello syndrome and HRAS amino acid change p.G13C show distinctive ectodermal findings (18) . Given the available data, further expansion of the phenotypic and functional variability associated with HRAS germline mutations has been proposed (19, 20) .
To attain a comprehensive picture of the phenotypic and functional variability, it is important both to delineate the clinical findings and to determine the functional consequences for novel HRAS sequence changes. Even if it is impossible to draw genotype -phenotype conclusions based on single patients, functional analyses will help to understand the underlying molecular deficiencies, thereby, providing a rational basis for possible therapeutic options. Here, we further document the broad phenotypic and functional variability associated with HRAS mutations by characterizing the novel HRAS p.E63_D69dup mutation.
RESULTS

Identification of a novel heterozygous HRAS mutation in a girl with clinical characteristics of Costello syndrome
The patient's clinical manifestations prompted the clinical diagnosis of Costello syndrome (Fig. 1A) . However, her phenotype was considered to represent the milder end of the clinical spectrum for this condition based on her relatively mild feeding problems and intellectual impairment. We detected the novel heterozygous 21 bp duplication c.187_207dup in exon 3 of HRAS in the patient's DNA (Data not shown). Genotyping of parental DNAs did not identify this alteration and confirmed paternity, indicating de novo occurrence of the HRAS c.187_207dup mutation (Data not shown). The HRAS c.187_207dup mutation was predicted to cause duplication of HRAS amino acids 63-69 (p.E63_D69dup) (Fig. 1B) . Five of these residues are integral part of the HRAS switch II domain (amino acids 59-67) that mediates binding of HRAS with various regulator and effector proteins (Fig. 1B) (10, (21) (22) (23) (24) . Of note, the p.E63_D69dup mutation represents the first germline molecular lesion affecting more than one amino acid in HRAS and, thereby, might exert strong impact on HRAS protein structure.
The p.E63_D69dup mutation increases HRAS co-precipitation with effector proteins RAF1, RALGDS and PLCE1, but not with PIK3CA in vivo
To explore the molecular consequences of the p.E63_D69dup mutation, we precipitated activated hemagglutinin (HA)-tagged HRAS protein variants from COS-7 cell extracts using glutathione S-transferase (GST)-fusion proteins of interacting motifs from various RAS effectors. Co-precipitation of HA-HRAS
G12S
and HA-HRAS G12V with any tested effector was strongly enhanced under steady-state cell culture conditions, including serum starvation (0.1% serum) and basal growth condition (10% serum) when compared with HA-HRAS WT ( Fig. 2A and  B) . In contrast, the dominant negative mutant HA-HRAS S17N (25, 26) was not pulled down efficiently ( Fig. 2A and B) . The amount of HA-HRAS E63_D69dup was similar to that of HA-HRAS G12S or HA-HRAS G12V in the RAF1, PLCE1 and RALGDS precipitates under serum-starved and basal conditions ( Fig. 2A and B) . However, it was decreased when compared with HA-HRAS WT in precipitates using PIK3CA as bait ( Fig. 2A and B ). These data suggest (i) that HA-HRAS E63_D69dup is trapped in an active conformation resulting in stabile binding to RAF1, PLCE1 and RALGDS and (ii) that the p.E63_D69dup mutation negatively affects binding to PIK3CA.
p.E63_D69dup affects HRAS interaction with NF1 GAP
HRAS has a low intrinsic GTPase activity that is dramatically stimulated by GAPs, and the switch II region is critical for GAP binding (10, 27, 28) . Thus, increased activation of HA-HRAS E63_D69dup as suggested by Figure 2 may result from impaired GAP interaction. To analyze binding of the RASspecific NF1 GAP, we co-expressed the GAP-related domain of NF1, called NF1 333 , together with HRAS protein variants in COS-7 cells and performed co-immunoprecipitation experiments. FLAG-tagged NF1 333 strongly co-precipitated with constitutively active HA-HRAS G12V or HA-HRAS G12S , but not with dominant negative HA-HRAS S17N (Fig. 3) . We could also pull down FLAG-NF1 333 together with HA-HRAS WT , most likely reflecting the fraction of active HA-HRAS WT molecules in the cell lysates (Fig. 3) . In contrast, FLAG-NF1 333 did not considerably co-precipitate with HA-HRAS E63_D69dup ( Fig. 3 ) which indicates that duplication of amino acids 63-69 in HRAS interferes with NF1 GAP binding.
HRAS E63_D69dup increases phosphorylation of MEK1/2 and ERK1/2
To gain insight into the consequences of the p.E63_D69dup mutation on HRAS-dependent downstream signaling, we determined levels of phosphorylated MEK1/2, ERK1/2 and AKT in COS-7 cells ectopically expressing HA-tagged HRAS protein variants. Whereas the dominant negative mutant HA-HRAS S17N induced only very weak downstream signaling ( Fig. 4A and B) , HA-HRAS G12V and HA-HRAS G12S were found to markedly stimulate MEK1/2, ERK1/2 and AKT phosphorylation both under serum-starved (Fig. 4A) and basal (Fig. 4B) conditions. Similarly, HA-HRAS E63_D69dup induced increased phosphorylation of downstream effectors under steady-state culture conditions when compared with HA-HRAS WT ( Fig. 4A and B) . In detail, the hyperactivation was more pronounced for MEK1/2 and ERK1/2 than for AKT ( Fig. 4A and B) . Together, the data suggest that p.E63_D69dup preferentially intensifies mitogenactivated protein kinase (MAPK) signal flux.
HRAS E63_D69dup shows residual reagibility to stimuli
Experiments with steady-state cell cultures are not informative concerning signaling dynamics. Therefore, we analyzed the intensity of downstream signaling upon epidermal growth factor (EGF) stimulation in transiently transfected COS-7 cultures. Serum-starved cells expressing HA-HRAS WT had low levels of phosphorylated MEK1/2, ERK1/2 and AKT that all increased markedly 10 min after EGF stimulation (Fig. 5A) . In contrast, expression of HA-HRAS G12V resulted in robust basal phosphorylation of MEK1/2, ERK1/2 and AKT even in starved cells and only moderate or no augmentation in response to EGF stimulation; the small increment in pMEK and pERK may, at least in part, derive from untransfected cells (Fig. 5A) . In Figure 1 . HRAS c.187_207dup (p.E63_D69dup) is associated with Costello syndrome. (A) Photographs of the patient at age 13 years. Note the typical facial features of a RASopathy, prematurely aged appearance, sparse hair and hyperkeratotic skin lesions at the ankles. (B) Position of amino acids 63-69 within the secondary structure of the HRAS GTPase. Secondary structural elements are shown as arrows and cylinders representing b-sheets and a-helices, respectively. Motifs representing the P-loop and switch I and II regions are indicated below the protein structure; amino acids (aa) constituting these motifs are given. The C-terminus of HRAS contains the membrane-targeting CVLS (Cys-Val-Leu-Ser) motif. HRAS has five conserved G motifs (G1 -G5, gray boxes) (56) . Amino acids 63-69 and duplicated residues are highlighted above the HRAS structure by gray background.
HA-HRAS
E63_D69dup expressing cells, we found elevated phosphorylation levels at baseline (0 min) and hence a reduced phosphorylation response ( To examine signaling dynamics in detail, we determined EGF response over time and statistically evaluated densitometric measurements of autoradiographs. Following EGF treatment, we detected strong activation of HA-HRAS WT and to a lesser extent of HA-HRAS E63_D69dup (Fig. 5B , Panels 1 and 2); EGF stimulation resulted in an increase in active HA-HRAS WT by 56% (from 44% at 0 min EGF to maximum activation of 100% after 15 min EGF), whereas activation of HA-HRAS E63_D69dup was enhanced only by 32% (from 68% at 0 min EGF to maximum activation of 100% after 15 min EGF) (Fig. 5C , top graph). In contrast, EGF had no effect on the activation of constitutively active HA-HRAS G12V ( Fig. 5B and C). The phosphorylation levels of HRAS effectors MEK1/2 and ERK1/2 correlated well with the amounts of active HRAS (Fig. 5B , Panels 3-6); EGF stimulation induced a strong phosphorylation response in HA-HRAS WT cells, whereas in cells expressing HRAS G12V , there was only little further increment. The residual activation in the latter case most likely originates from untransfected cells in the cultures. EGF-induced phosphorylation increment of MEK1/2 and ERK1/2 in cells expressing HA-HRAS E63_D69dup was weaker than in HRAS WT cells, but significantly stronger than in HRAS G12V cells (Fig. 5C , second and third graph). This suggests that HRAS E63_D69dup is able to transmit EGF stimulation to MAPK signaling cascades with an efficiency that is in between that of HRAS WT and HRAS G12V . AKT phosphorylation, however, only marginally increased upon EGF treatment in cells expressing , HA-HRAS G12S , HA-HRAS G12V or HA-HRAS S17N were cultured under serum-starved [0.1% serum, (A)] or basal [10% serum, (B)] growth conditions. GTP-bound HA-tagged HRAS protein variants were precipitated from cell extracts using GST-RAF1:RBD, GST-PLCE1:RA, GST-RALGDS:RA or GST-PIK3CA:RBD fusion proteins as indicated (RBD, RAS binding domain; RA, RAS association domain). Vector controls are shown in the first lane each. Precipitated HA-HRAS (precipitates) and total amounts of HA-HRAS proteins in the cellular extracts (tcl) were detected by immunoblotting using anti-HA antibody. Cellular extracts were probed with anti-GAPDH antibody to control for equal loading. Representative blots from three independent experiments are shown. tcl, total cell lysates.
HRAS
E63_D69dup (Fig. 5B , Panels 7 and 8). This was very similar to HRAS G12V cells, but not to HRAS WT transfected cultures that showed a strong AKT phosphorylation response upon EGF stimulation ( Fig. 5B and C ). This finding is in line with the observation of a reduced interaction of HRAS E63_D69dup with the AKT upstream regulator subunit PIK3CA (Fig. 2) .
Taken together, our data suggest that in addition to restricting PI3K binding, the p.E63_D69dup mutation moderately increases HRAS basal activation, resulting in a limited capacity to modulate signaling.
DISCUSSION
The functional analysis of rare Costello syndrome-associated HRAS mutations can improve the understanding of the molecular deficiencies underlying this disorder. With the identification and characterization of the p.E63_D69 mutation here, we add novel aspects to the knowledge of HRAS dysfunction and shift the focus from harmful HRAS hyperactivation toward pathologic hyporeagibility to stimuli.
Functional consequences
HRAS mutations that cause Costello syndrome are associated with increased HRAS activation and enhanced RAF-MAPK and/or PI3K-AKT signal flow (5, 12, 14, 16, 17, 29) . Using RAF1, PLCE1 or RALGDS in cellular GTPase activation assays, we could co-precipitate increased amounts of HRAS E63_D69dup from cell extracts (Fig. 2) ; this suggests that the p.E63_D69dup mutation results in hyperactivation of HRAS that is generally in line with the effects of other Costello syndrome-associated HRAS mutations. Notably, we detected increased amounts of active HRAS E63_D69dup both under serum-starved and basal conditions (Fig. 2) (12, 29) .
Amino acids 63 -69 constitute integral components of the highly mobile switch II region (Fig. 1B) that is involved in binding regulator proteins, including GAPs, GEFs and GDP dissociation inhibitors as well as effector molecules and GDP/GTP nucleotides (10, (21) (22) (23) (24) . Here, we demonstrate impaired binding of HRAS E63_D69dup with NF1 GAP (Fig. 3) , suggesting that the p.E63_D69dup mutation strongly interferes with the structure of the switch II region that is critical for interaction with GAPs such as NF1 and p120GAP (10, 27, 28) . Recently, altered GAP binding has been shown for another Costello syndrome-associated HRAS change, the duplication of glutamic acid at position 37 (HRAS E37dup ) in the switch I region of HRAS (13) . Our data indicate that, similar to the HRAS E37dup mutant, HRAS E63_D69dup accumulates in the GTP-bound form due to substantially reduced GAP affinity.
We could not co-precipitate HRAS E63_D69dup using PIK3CA, the catalytic subunit of PI3K (Fig. 2) , that makes critical interactions with the switch II region (30, 31) . Similarly, substitution of HRAS tyrosine 64 by a glycine eliminated the interaction with PI3K and also with NF1, whereas this substitution had no effect on RAF1 binding (32) . Indeed, the effector proteins RAF1 and RALGDS interact with switch I, but not switch II of RAS (21) . PLCE1 is able to make contact with both switch I and switch II, thereby, sharing this ability with PI3K (33) . Assuming a distorted structure of the HRAS E63_D69dup switch II region, our results indicate that PLCE1 interaction with switch I is sufficient for effective binding (Fig. 2) . Thus, p.E63_D69dup may specifically impair interaction with PIK3CA, but not with RAF1, RALGDS and PLCE1.
In line with the results derived from GTPase activation assays, HRAS E63_D69dup induced strong phosphorylation of RAF1 downstream effectors MEK1/2 and ERK1/2 both under serum-starved and basal conditions (Fig. 4) , suggesting a constitutive activating effect of the p.E63_D69dup mutation. On the contrary, phospho-AKT was found to be only marginally elevated in cells expressing HRAS E63_D69dup (Fig. 4) , a consequence obviously originating from impaired PI3K binding to activated HRAS E63_D69dup . Costello syndrome-associated HRAS mutations exert their pathogenic consequences by gain-of-function of HRAS-dependent signal transduction resulting in enhanced RAF1-MEK-ERK and PI3K-AKT signal flux (12, 34) . The p.E63_D69dup mutation, however, Figure 3 . The p.E63_D69 mutation impairs binding of NF1 GAP. COS-7 cells were transfected with expression constructs as indicated and cultured under basal growth conditions (10% serum). Vector control is shown in lane 1. HA-tagged HRAS protein variants were immunoprecipitated from cell extracts using anti-HA-conjugated agarose beads. Upon SDS PAGE and western blotting, precipitates and total cell lysates (tcl) were probed with anti-HA and anti-FLAG antibodies.
has two independent molecular consequences: First, a gain-of-function effect results in the accumulation of activated HRAS E63_D69dup and positively modulates RAF-MEK-ERK downstream signaling. And, second, p.E63_D69dup impairs the interaction with PIK3CA that counteracts the gain-of-function effect and leads to apparently normal PI3K-AKT signal transduction. Similarly, the Costello syndrome-associated p.E37dup mutation promotes mildly enhanced HRAS-dependent signaling that results from a balancing effect between a GAP insensitivity and inefficient effector binding (13) .
If HRAS E63_D69dup is constitutively active, the sensitivity for EGF-induced HRAS E63_D69dup activation and the ability of HRAS E63_D69dup to respond to upstream signals should be diminished or abolished. Our results, however, suggest that HRAS E63_D69dup retained significant reagibility to stimuli and is still able to transmit growth factor-derived signals to MAPK cascades; this is in contrast to HRAS G12V that is fully active without EGF stimulation (Fig. 5) . Growth factorindependent downstream signaling is caused by HRAS mutations (p.G12V, p.G12S, p.K117R and p.A146T) that affect amino acids involved in GDP/GTP binding or guanosine triphosphate reaction (5, 12, 16, 29) . On the other side, effector/GAP binding-impaired HRAS E37dup potentiated downstream signal flow only upon growth factor stimulation (13) . Therefore, we suggest that the p.E63_D69dup mutation may not dramatically affect nucleotide binding or intrinsic GTP hydrolysis, but rather alters GAP/effector binding; and the latter molecular deficiencies do not fully abolish signal transducing properties of HRAS.
We observed very weak AKT phosphorylation in response to EGF stimulation both in cells expressing HRAS G12V and HRAS E63_D69dup (Fig. 5) ; however, the molecular basis for this weak AKT signaling differs between HRAS G12V and HRAS E63_D69dup cells: Whereas constitutive active HRAS G12V results in strong hyperphosphorylation of AKT even under serum starvation and, therefore, a very weak signaling response, HRAS E63_D69dup is not able to transmit upstream signaling to the PI3K-AKT cascade due to impaired PIK3K interaction.
Taken together, available data nicely demonstrate that the consequences of Costello syndrome-associated HRAS mutations on downstream signaling are variable and strongly depend on the quality of the molecular defect. In analogy, five different mechanistic classes with aberrant biochemical and ] conditions, and cell extracts were analyzed by immunoblotting using specific antibodies. The representative autoradiographs show levels of total MEK1/2, phospho-MEK1/2, total ERK1/2, phospho-ERK1/2, total AKT, phospho-AKT Ser473 and phospho-AKT Thr308 . Expression of HA-tagged HRAS variants in total cell extracts was demonstrated by immunoblotting using anti-HA antibody, and blots were probed with anti-GAPDH antibody to control for equal loading. tcl, total cell lysates. physical properties have been determined for rasopathy-associated KRAS germline mutation (35) . Our data indicate that the p.E63_D69dup mutation leads to gain-of-function of HRAS-RAF-MAPK signaling, but, concurrently, it has apparently little impact on the HRAS-PI3K-AKT signaling cascade. We suggest that both consequences are based on a massively altered HRAS E63_D69dup protein topology impairing GAP binding and PI3K interaction.
Reduced reagibility, oncogenic-induced senescence and Costello syndrome
The p.E63_D69dup mutation results in a reduced reagibility to stimuli (Figs 5). In principle, constitutive hyperactivation of HRAS due to any Costello syndrome-associated or oncogenic HRAS mutation can be also interpreted as a reduction in HRAS reagibility to stimuli. Insensitivity to physiologic stimuli is a major characteristic of cellular senescence, a state of irreversible cellular growth arrest participating in different complex biologic processes, including tumor suppression/progression, tissue repair and aging (36) . Cellular senescence can be triggered by various mechanisms such as telomere shortening, epigenetic de-repression or excess of mitogenic signals (37) . The latter trigger can be delivered by certain oncogenic mutants such as the BRAF V600E or the HRAS G12V oncoproteins, thereby it is called oncogenic-induced senescence (38) . In fact, expression of HRAS G12V in a zebrafish model of Costello syndrome caused cellular senescence, but not overt constitutive activation of HRAS targets (39) . Moreover, it has been demonstrated that, like HRAS G12V , several other Costellosyndrome associated HRAS mutants (p.G12S, p.G12A, p.G12C, p.G12D, p.G13C, p.G13D, p.K117R and p.A146T) induce cellular senescence when overexpressed in human fibroblasts (40) . The authors proposed that cellular senescence might contribute to the pathogenesis of Costello syndrome. Interestingly, results from molecular studies strongly suggest cellular senescence as one of two underlying mechanisms of pathologic premature ageing in the Hutchinson -Gilford progeria (OMIM #176670) and Werner (OMIM #277700) syndromes (reviewed in 41). Older individuals with Costello syndrome display features of premature aging such as hair loss and prematurely aged skin (1) that can also been seen in the patient presented here (Fig. 1A) . Taken together, these observations may suggest that, in addition to hyperactivation of HRAS signaling G12V were serum starved (0.1% serum) and subsequently stimulated with 10 ng/ml EGF for various times (5, 15, 30 min EGF) or left untreated (0 min EGF) as indicated. GTP-bound HA-HRAS was precipitated from cell extracts using GST-RAF1:RBD fusion protein. Total amounts of HA-HRAS in the total cell lysates (tcl) and precipitated HA-HRAS (pcpt) were detected using anti-HA antibody. Cellular extracts (tcl) were also analyzed by immunoblotting using specific antibodies against total MEK1/2, phospho-MEK1/2, total ERK1/2, phospho-ERK1/2, total AKT and phospho-AKT
Ser473
. Equal loading was confirmed by immunoblotting for GAPDH. (C) After densitometric quantification of autoradiographic signals, levels of active HA-HRAS, phosphorylated MEK1/2, ERK1/2 and AKT were normalized relative to levels of total HA-HRAS, MEK1/2, ERK1/2 and AKT, respectively. Subsequently, maximum HA-HRAS activation levels and maximum MEK1/2, ERK1/2 and AKT phosphorylation levels were considered 100% for each stimulation series of cells expressing the indicated HRAS variants. Thus, the graphs show activation and phosphorylation levels upon 0, 5, 15 and 30 min EGF stimulation relative to maximum levels in cells expressing HRAS WT , HRAS E63_D69dup or HRAS
G12V
. The number of independent experiments (n) is indicated, and the data represent the mean of n independent experiments. For untreated cells, (0 min EGF) + standard deviation is given, and a statistical analysis was performed. Significance levels are specified between two data points on the respective curves [ * , P,0.05; ns, statistically not significant (Student's t-test)].
pathways, cellular senescence coupled with growth factor resistance during development may represent a second line of pathophysiology in Costello syndrome. In line with this hypothesis and based on experiments with primary fibroblasts of patients with Costello syndrome, it has been proposed that altered cellular response to growth factors rather than constitutive activation of HRAS downstream signaling molecules may contribute to the phenotype (34) . This hypothesis is corroborated by the analysis of an HRAS WT/G12V mouse model for Costello syndrome that showed normal phosphorylation levels of Erk, Mek and Akt in all tissues tested (42) . These considerations also have important implications on the research regarding future treatment strategies because inhibitors of the pathway may influence its basal activity, but not be able to restitute its dynamics.
Cell physiologic basis of phenotypic variability
The typical Costello syndrome phenotype is easily recognizable in older individuals, and it is most often due to a substitution of HRAS glycine at position 12 for a serine (1). Rarer HRAS mutations can be associated either with a more severe clinical presentation (17,43 -45) or with milder findings (14, 16, 18) . Notably, substantially attenuated clinical features are caused by mutations affecting other amino acids than glycine 12 and 13 in the P-loop of HRAS (p.Q22K, p.E37dup, p.T58I, p.E63K, p.K117R and p.A146T/V), thereby, representing the mild end of the Costello syndrome phenotype (12 -17) . Although it is difficult to draw definite conclusions from a single observation, the clinical expression of the syndrome in our patient suggests that the p.E63_D69dup mutation may rather belong to the latter group. Phenotypic differences of patients with Costello syndrome may mirror dissimilar molecular pathomechanisms: Whereas mutations of HRAS glycine 12 or 13 result in impaired intrinsic/GAP-stimulated GTPase activity (10), non-P-loop alterations such as HRAS K117R and HRAS E37dup are characterized by altered nucleotide binding affinities and impaired regulator/effector interaction, respectively (12, 13) . In line with this, HRAS E63_D69dup also shows impaired regulator (NF1) and effector (PIK3CA) binding.
Because HRAS E63_D69dup induces hyperstimulation of the RAF-MAPK, but not the PI3K-AKT signaling cascade, it is tempting to speculate that it is primarily the excess of RAF-MAPK signaling that underlies the Costello syndrome phenotype of our patient. However, by changing the perspective from hyperstimulation to hyporeagibility of HRAS-dependent signaling, we found both the RAF-MAPK and the PI3K-AKT cascade to be affected. Therefore, the correlation of the clinical features in our patient with the alteration of a specific signaling pathway is not possible. This is in line with other reports showing that Costello syndrome-associated HRAS alterations modify signaling via various effectors (13, 34, 46, 47) . Notably, deregulated PI3K-AKT signaling has been associated with various overgrowth syndromes such as Proteus syndrome, (hemi)megalencephaly syndromes or fibroadipose hyperplasia (48) (49) (50) (51) (52) . Accordingly, altered PI3K-AKT signaling may underlie progressive postnatal cerebellar overgrowth and fetal overgrowth that are frequently diagnosed for patients with Costello syndrome (53, 54) .
The functional characterization of unusual HRAS mutations helps to put forward new hypotheses of molecular pathomechanisms and, thereby, enables a better understanding of the molecular basis of the phenotypic variability associated with pathogenic HRAS alterations. Noteworthy, a germline HRAS alteration (c.266C.G; p.S89C) has been previously reported in two siblings with clinical features that only marginally resemble the Costello syndrome phenotype (19) . This alteration resulted in decreased EGF-induced HRAS downstream signaling that also can be interpreted as reduced reagibility/reactivity. In conclusion, available data strongly suggest that the phenotypic spectrum and the functional variability associated with germline mutations in HRAS will further expand in the future.
MATERIALS AND METHODS
Case presentation
The 18-year-old female patient is the offspring of a healthy, consanguineous couple (third degree cousin marriage) from Turkey. Paternal and maternal ages at conception were 38 and 25 years, respectively. The patient was born at term by normal delivery at home after an uneventful pregnancy. Her birth measurements were not recorded. The parents reported feeding difficulties and muscular hypotonia during infancy and childhood. Tube feeding was not required. The patient started to sit and to walk without support at 12 and 24 months of age, respectively. Development of speech was mildly delayed. She was admitted to a hospital with the complaints of skin lesions and easy fatigability at the age of 5 years, when she was diagnosed to have hypertrophic cardiomyopathy. She was, therefore, treated with propranolol. At the age of 8 years, osteoporosis was diagnosed, and vitamin D treatment was initiated. The patient was 13 years old, when she was first evaluated at Ihsan Dogramaci Children's Hospital. Physical examination revealed short stature with a body height of 141 cm (,3rd centile), a body weight of 33 kg (,3rd centile) and relative macrocephaly with an occipitofrontal head circumference of 55 cm (75th centile). She had coarsened facial features, bulging eyes with ptosis and hypertelorism, low-set ears, thin, sparse and curly hair, multiple lentigines particularly on the face and a relatively dark pigmentation of the skin (Fig. 1) . The palms and soles were soft with deep creases. Plaque-like hyperkeratotic skin lesions were visible around her ankles. Mild skeletal abnormalities such as genu varum, pes planus and mild ulnar deviation at the wrists were also noted. Echocardiography revealed hypertrophic cardiomyopathy without obstruction, dilated coronary sinus, malalignment of the aorta and mitral and pulmonary insufficiencies. Electrocardiography demonstrated sinus tachycardia and first degree AV block. Mild intellectual disability along with good verbal communication skills was noted (a formal psychometric evaluation is not available). The patient is currently attending a regular school with additional support. She has not had any oncologic manifestations, so far. Based on the clinical features, the diagnosis of Costello syndrome was made.
Molecular genetic analysis
We collected blood samples of the patient and her parents and isolated genomic DNA from lymphocytes by standard procedures. We amplified the coding region, including the flanking intronic sequences of the HRAS gene (GenBank accession nos. NM_005343.2 and NM_176795.3) from genomic DNA. Primer sequences are available on request. Mutation analysis of the amplimers was carried out by direct sequencing bidirectionally, using the ABI BigDye terminator Sequencing Kit v.3.1 (Applied Biosystems, Life Technologies, Biosystems, Weiterstadt, Germany) and an ABI 3700 Capillary Array Sequencer (Applied Biosystems). We verified the declared relationship by genotyping of the parents and the patient at 10 microsatellite loci. Ethical approval for this study was obtained, and the parents provided informed written consent for the genetic analysis.
Plasmids
We amplified the coding region of wild-type HRAS for the generation of an expression construct using HRAS-specific PCR primers and HRAS cDNA as a template. Mutated HRAS cDNA inserts [c.34G.A (p.G12S), c.35G.T (p.G12V), c.50G.A (p.S17N) and c.187_207dup (p.E63_D69dup)] were established by PCR-mediated mutagenesis. Purified PCR products were cloned into pENTR/D-TOPO (Invitrogen, Karlsruhe, Germany) according to the protocol provided. Constructs were sequenced for integrity and used for transferring wild-type and mutated HRAS coding regions into plasmid pMT2SM-HA-DEST (N-terminal HA epitope). NF1 333 in pcDNA3-FLAG contains residues 1198 -1530 of human NF1 comprising the functional GAP-related domain that is able to bind to wild-type HRAS and stimulate GTP hydrolysis.
Cell culture and transfection
COS-7 cells were cultured in Dulbecco's Modified Eagle Medium (DMEM; Invitrogen) containing 10% serum (Invitrogen) and penicillin -streptomycin (100 U/ml and 100 mg/ml, respectively) (Invitrogen) at 378C and 5% CO 2 . Transfections were performed using Lipofectamine 2000 Reagent (Invitrogen) according to the manufacturer's protocol. For EGF stimulation, cells were blocked overnight by serum starvation (0.1% serum), followed by incubation in DMEM containing 10 ng/ ml EGF (Sigma, Taufkirchen, Germany).
RAS activation assay
The RAS-binding domain (RBD) of RAF1 (amino acids 51-131), the RBD of PI3K (PIK3CA) (amino acids 127-314), the RAS-association (RA) domain of RALGDS (amino acids 777-872) and the RA domain of PLC1 (PLCE1) (amino acids 2130 -2240) were used to specifically precipitate GTP-bound RAS proteins from cell extracts (55) . Preparation of GST-RBD/RA beads, cell lysis and precipitation of GTP-bound RAS have been described elsewhere (34) . After SDS PAGE and transfer to polyvinylidene difluorid (PVDF) membranes, total and precipitated (active) HA-tagged HRAS was detected using peroxidase-conjugated rat monoclonal anti-HA antibody (Roche, Mannheim, Germany; clone 3F10; 1:5000 dilution). For loading control, membranes were incubated with mouse anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Abcam, Cambridge, UK; no. ab8245, 1:5000 dilution), followed by peroxidase-coupled secondary anti-mouse antibody (Amersham Pharmacia Biotech, Freiburg, Germany; no. NA9310; 1:8000 dilution).
Co-immunoprecipitation
Transiently transfected COS-7 cells were lyzed in ice-cold cell lysis buffer [150 mM Tris -HCl, pH 8.0; 50 mM NaCl; 1 mM EDTA; 0.5% Nonidet P-40; complete Mini Protease Inhibitors (Roche); 0.7 mg/ml Pepstatin] and cell extracts were clarified by centrifugation. The supernatants were transferred to 40 ml EZview TM Red Anti-HA Affinity Gel (Sigma) and incubated for 2 h at 48C on a rotator. Precipitates were collected by repeated centrifugation and washing with cell lysis buffer, re-suspended in sample buffer (33% glycerol; 80 mM TrisHCl, pH 6.8; 0.3 M Dithiothreitol; 6.7% sodium dodecyl sulphate; 0.1% bromophenol blue) and subjected to SDS PAGE and immunoblotting.
Immunoblotting
Twenty-four hours after transfection, cells were cultured as specified, then washed with PBS and scraped off in modified radioimmunoprecipitation assay buffer [50 mM Tris-HCl, pH 8.0; 150 mM NaCl; 1% Nonidet P-40; 0.5% sodium deoxycholate; 0.1% SDS; 1 mM phenylmethylsulfonyl fluoride; 1 mM Na 3 VO 4 ; 10 mM NaF; 1 Complete Mini protein inhibitor cocktail tablet (Roche) per 10 ml]. Cellular biochemical reactions were stopped by freezing lysates in liquid nitrogen. After thawing on ice, cell debris was removed, and protein concentration was determined using the BCA Protein Assay Kit (Pierce, Bonn, Germany). Protein solutions were supplemented with sample buffer, and proteins were separated on SDS-polyacrylamide gels and transferred to PVDF membranes. Following blocking (20 mM Tris-HCl, pH 7.4; 150 mM NaCl; 0.1% Tween-20; 4% non-fat dry milk) and washing (20 mM Tris-HCl, pH 7.4; 150 mM NaCl; 0.1% Tween-20), membranes were incubated in primary antibody solution (20 mM Tris-HCl, pH 7.4; 150 mM NaCl; 0.1% Tween-20; 5% BSA or 0.5% non-fat dry milk) containing the appropriate antibodies. Rabbit polyclonal antibodies against MEK1/2 (Cell Signaling Tech., Danvers, MA, USA; no. 9122; 1:1000 dilution), phospho-MEK1/2 (Ser217/221) (Cell Signaling Tech.; no. 9121; 1:1000 dilution), p44/42 MAP kinase (ERK1/2) (Cell Signaling Tech.; no. 9102, 1:1000 dilution), phospho-p44/42 MAP kinase (ERK1/2) (Thr202/Tyr204) (Cell Signaling Tech.; no. 9101, 1:1000 dilution), Akt (Cell Signaling Tech.; no. 9272; 1:1000 dilution), phospho-Akt (Ser473) (Cell Signaling Tech.; no. 9271; 1:1000 dilution) and phospho-Akt (Thr308) (Cell Signaling Tech.; no. #9275; 1:1000 dilution) were used. Next, membranes were washed and incubated with peroxidase-coupled secondary anti-rabbit antibody (Amersham Pharmacia Biotech; no. NA9340V; 1:8000 dilution). After final washing, immunoreactive proteins were visualized using the Immobilon Western Chemiluminescent HRP Substrate (Millipore, Schwalbach, Germany).
Statistical analysis
Signals on autoradiographs from three independent experiments were quantified by densitometric analysis using the ImageJ software (NIH; http://rsb.info.nih.gov/ij/index.html). MEK1/2, ERK1/2 and AKT phosphorylation as well as HRAS activation levels were assessed as described in Figure 5C . A two-tailed unpaired Student's t-test was used to determine the significance of the difference between cells overexpressing HRAS mutants. Values are presented as the mean + standard deviation and were considered significant at P-value,0.05. 
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